Nasdaq cprx.
That number of contracts represents approximately 884,100 underlying shares, working out to a sizeable 52.9% of CPRX's average daily trading volume over the past month, of 1.7 million shares.
A look at the shareholders of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership.Hedge fund activity in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) At the end of the third quarter, a total of 12 of the hedge funds tracked by Insider Monkey held long positions in this stock, a ...For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ...Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ...
Stock analysis for Catalyst Pharmaceuticals Inc (CPRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $16.44, marking a +1.99% move from the previous day. This change outpaced the S&P 500's 0.17% gain on the day.
Analyst Future Growth Forecasts. Earnings vs Savings Rate: CPRX's forecast earnings growth (25.8% per year) is above the savings rate (2.2%). Earnings vs …
(NASDAQ: CPRX) Catalyst Pharmaceuticals currently has 106,582,857 outstanding shares. With Catalyst Pharmaceuticals stock trading at $12.85 per share, the total value of Catalyst Pharmaceuticals stock (market capitalization) is $1.37B .The intraday chart, the last-five real-time quotes and sales data. Real-time stock quotes can be used to help inform investors when researching potential investment opportunities. Tesla, Inc ...Sep 21, 2022 · The average CPRX stock price target of $16.70 per share implies 34% upside over the next twelve months. A strong rally in Catalyst Pharmaceuticals stock might have been amplified by institutional ... A couple of Nasdaq stocks saw particularly sharp declines Wednesday morning that stemmed from bad news in their respective businesses. American Airlines Group ( AAL 3.66%) warned that its first ...Catalyst Pharmaceuticals (NASDAQ:CPRX) Insider Buying and Selling Activity. Current Insider Ownership Percentage 12.10%. Number Of Insiders Buying (Last 12 Months) 0. Number Of Insiders Selling (Last 12 Months) 6. Amount Of Insider Selling (Last 12 Months) $4.07 M. Get CPRX Insider Trade Alerts.
CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ...
Find the latest dividend history for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological ...Find the latest SEC Filings data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. Find the latest historical data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Sep 21, 2022 · The average CPRX stock price target of $16.70 per share implies 34% upside over the next twelve months. A strong rally in Catalyst Pharmaceuticals stock might have been amplified by institutional ... CPRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Catalyst Pharmaceuticals, Inc. is based on the …Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...
January 24, 2023 — 12:26 pm EST. Written by Zacks Equity Research for Zacks ->. Shares of Catalyst Pharmaceuticals CPRX were down 29.0% on Jan 24 after management announced that it had received ...Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological ...The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...Most readers would already be aware that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased significantly by 9.4% over the past month. Since the market usually pay for a company’s long-term ...Aug 9, 2023 · CORAL GABLES, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “the Company”) (Nasdaq: CPRX) today reported financial results for the second quarter of 2023 and provided a corporate update. (NASDAQ:CPRX), announced on June 20, 2023 [1]. The proceeds from the agreement extend Santhera's cash reach into 2025. Together with the expected income ...Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company that focuses on therapies for rare debilitating, chronic neuromuscular, and neurological ...
Back to CPRX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.
January 24, 2023 — 12:26 pm EST. Written by Zacks Equity Research for Zacks ->. Shares of Catalyst Pharmaceuticals CPRX were down 29.0% on Jan 24 after management announced that it had received ...CPRX technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Catalyst Pharmaceuticals, Inc. is based on the …09/26/2022. 5.23%. 95,058,928. 4,970,704. 7,496,361. 1. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Catalyst Pharmaceuticals gives investors a ...Catalyst Pharmaceuticals last released its quarterly earnings data on November 8th, 2023. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). The business earned $102.69 million during the quarter, compared to the consensus estimate of $100.17 million. Earnings vs Savings Rate: CPRX's forecast earnings growth (25.8% per year) is above the savings rate (2.2%). Earnings vs Market: CPRX's earnings (25.8% per year) are forecast to grow faster than the US market (14.7% per year). High Growth Earnings: CPRX's earnings are expected to grow significantly over the next 3 years.Find the latest on option chains for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Find the latest SEC Filings data for Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.16 per share a year ago.A couple of Nasdaq stocks saw particularly sharp declines Wednesday morning that stemmed from bad news in their respective businesses. American Airlines Group ( AAL 3.66%) warned that its first ...Stock analysis for Catalyst Pharmaceuticals Inc (CPRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Will Weakness in Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Prove Temporary Given Strong Fundamentals? (Simply Wall St.) Jul-19- ...
AlSimonov/iStock via Getty Images. This is my fifth Catalyst (NASDAQ:CPRX) article following 04/2023's "Catalyst Pharmaceuticals: Fixing Its Misnomer Is No Easy Task".My concern with Catalyst is ...
Dec 28, 2022 · Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ... Swiss National Bank raised its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 2.4% in the 2nd quarter, Holdings Channel …Dec 29, 2022 · Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ... Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ...Sep 21, 2022 · The average CPRX stock price target of $16.70 per share implies 34% upside over the next twelve months. A strong rally in Catalyst Pharmaceuticals stock might have been amplified by institutional ... This value model looks for companies with high return on capital and earnings yields. CATALYST PHARMACEUTICALS INC ( CPRX) is a small-cap value stock in the Biotechnology & Drugs industry. The ...CPRX earnings call for the period ending September 30, 2021. Image source: The Motley Fool. Catalyst Pharmaceuticals, inc ( CPRX -1.16% ) Q3 2021 Earnings Call Nov 10, 2021 , 8:30 a.m. ETAug 5, 2023 · This value model looks for companies with high return on capital and earnings yields. CATALYST PHARMACEUTICALS INC ( CPRX) is a small-cap growth stock in the Biotechnology & Drugs industry. The ... Apr 13, 2021 · A look at the shareholders of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Based in Coral Gables, Florida, Catalyst Pharmaceuticals (NASDAQ:CPRX) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people ...If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...14 jam yang lalu ... Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and ...
Overview News Catalyst Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data 26.66 ( 11/24/23) EPS (TTM) $0.53 Market Cap $1.50 B CPRX N/A N/A Short Interest ()...CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive ...Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Mar 22, 2023 · Shares of Catalyst Pharmaceutical (CPRX) have gained 8.4% over the past four weeks to close the last trading session at $16.53, but there could still be a solid upside left in the stock if short ... Instagram:https://instagram. nysearca vwotesla a buy1964 50 cent piece valuereits to buy now ... Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza ... nvidia stock buybackdeep value etf Catalyst Pharmaceuticals, inc (CPRX) Q2 2021 Earnings Call Transcript CPRX earnings call for the period ending June 30, 2021. Motley Fool Transcribers | Aug 10, 2021CPRX U.S.: Nasdaq Catalyst Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023 7:46 p.m. EST Delayed quote $ 13.68 -0.13 -0.94% After Hours... best medicare supplement plans minnesota Per the terms of the agreement, CPRX is liable to make an upfront payment of $75 million to Santhera, along with a concurrent strategic equity investment of $15 million into Santhera.Noteworthy ETF Inflows: XBI, BBIO, HALO, CPRX. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ...CPRX | Complete Catalyst Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.